Judge halts sale of Rick Ware Racing's NASCAR team amid legal battle with Legacy Motor Club
The order remains in place for 10 days and Legacy is required to post a bond of $5 million by end of business Friday. Rick Ware Racing's attorneys had requested the bond amount be set at $150 million — the agreed purchase price between RWR and Puchyr, one of the founders of Spire Motorsports who now is a consultant to various race teams and sponsors.
Legacy is suing RWR over a dispute stemming from an agreement that Puchyr brokered for Johnson's race team to purchase one of Ware's two charters. The dispute is over which charter Ware agreed to sell and if the deal is for 2026 or 2027.
A charter is NASCAR's version of a franchise tag and guarantees teams entry into every race, plus monetary assurances. Ware currently uses one of his charters to field a full-time car for his son, Cody, and leases a second charter to RFK Racing.
Before he entered into a deal to sell a charter to Legacy, he already had an agreement with RFK to swap the charters currently in play and lease the other one to RFK in 2026. Then, in 2027, Ware planned to sell a charter outright to Legacy, which has a major investment from Knighthead Capital Management, a private equity firm worth over $13 billion.
Legacy requested both a preliminary injunction and temporary restraining order, in arguing Ware 'has shown a willingness to lie to Legacy and to the Court about the status of the deal,' after Puchyr announced his plans in June to buy RWR's NASCAR team.
Puchyr had negotiated the charter sale and Ware had previously stated he had no intention of selling or otherwise transferring the charters while the lawsuit was pending.
Mecklenburg Superior Court Judge Clifton Smith issued a verbal order entering a temporary restraining order Thursday that blocks any sale for 10 days. Smith will consider Legacy's request for a preliminary injunction.
Mark Henriques, counsel for Rick Ware Racing, argued both Ware and Puchyr intend to honor any deals but cannot meet the current terms of the charter purchase for 2026 based on the existing deal to lease a charter to RFK next season. RWR and Puchyr have said the plan is to lease to RFK in 2026 and sell to Legacy in 2027; Legacy says if Ware is selling to Puchyr, the charters contractually should be sold to Legacy.
'What we know is that these promises were made and this backdoor transaction was apparently entered into and is apparently a binding agreement, although not yet closed,' Legacy attorney Keith Forst said. 'There is really no harm to defendant whatsoever, and there is tremendous harm to plaintiff Legacy if this closing of these assets in fact happens.'
Thursdays
Keep up to date on sports with Mike McIntyre's weekly newsletter.
Ware's attorney disagreed and argued that Ware is trying to stay in business as a one-car team fielded for his son. Puchyr has made clear he intends to keep Cody Ware in the lineup after he buys the assets from Rick Ware.
'My clients did exactly what they had the freedom to do, work out a deal that meets the needs of the entity, and enter into a binding transaction that covers the entire business and yet keeps Cody racing,' said Henriques. 'They're trying to have their cake and eat it too since they lost the first preliminary injunction.'
Trial is currently scheduled for January, but Legacy has filed a second suit against Puchyr for interfering with its deal with Ware. Legacy has also terminated its consulting agreement with Puchyr.
___
AP auto racing: https://apnews.com/hub/auto-racing
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Ottawa Citizen
2 days ago
- Ottawa Citizen
Tom Mayenknecht: Tennis finds new star in Canadian Victoria Mboko; NFL also has big week
Article content Bulls of the week Article content It was a bullish week for both the National Football League and ESPN, with the NFL gaining a 10 per cent stake in the American cable giant and the Disney-owned sports network taking on the rights to and operations of NFL Network and Red Zone TV. It's a game-changing deal for the way leagues and their media rights holders relate to one another, on and off the field, so to speak. Watch for it to lead to many similar arrangements involving other leagues and their rights holders. It will only further elevate the upside and preferred position held by official rights holders, not only in the NFL but across all major men's and women's professional sports leagues operating in North America. Yet it will also lead to ongoing scrutiny and second-guessing of league decisions given the coziness and high stakes of the ownership relationship. Article content Article content Article content The Toronto Blue Jays had an all-time franchise-high of 45 runs scored over a three-game series as they swept the hapless Colorado Rockies in lopsided fashion this week (15-1, 10-4 and 20-1). They also became the first Major League Baseball franchise since 1900 to amass 63 hits in a three-game series, with 13 home runs, 13 doubles, one triple and 36 singles. The Jays go into the weekend with a 68-48 record, 20 games above .500 and four games ahead of the Boston Red Sox in the American League East. The Rockies series was a lot of fun for the Jays and their fans, but make no mistake, their opposition will be a lot tougher against the 66-49 Los Angeles Dodgers, 66-48 Chicago Cubs and 60-56 Texas Rangers over the next week. Article content Article content Yet the biggest winner this week in the business of sport was Canadian 18-year-old Victoria Mboko of Burlington, Ont. She became the third Canadian woman to win the National Bank Open presented by Rogers (Canadian Open), following in the footsteps of 2019 champion Bianca Andreescu. Mboko's ascent to tennis champion and Canadian sports hero is both improbable and remarkable, as was her final match win over four-time Grand Slam women's singles champion Naomi Osaka (2-6, 6-4, 6-1). Wins over four Grand Slam major champions will take her from a world ranking of 85th to begin the tournament to within the top-25 on the WTA Tour. This from a player who began the year outside of the top-300 in the world. Article content Article content To put the sport business side of the Mboko story into proper context, consider this: She earned $752,275 for the win. That single tournament score is more than her year-to-date career earnings of $458,001. She's now 53-9 in 2025, coming off only her seventh time playing in a WTA Tour main draw. Article content Perhaps most unfathomable about the come-from-behind win over Osaka is that Mboko was playing with a wrist injury suffered the night before in her semifinal win over former Wimbledon champion Elena Rybakina. Article content Article content The flip side of the big three-game sweep at Coors Field in mile high Denver is how pathetic the Rockies are. It's an embarrassment to baseball that a team can be 30-84, winning barely once every four games; 35.5 games behind in the National League West. Article content Yet arguably the biggest bears of the week are the New York Yankees, 4-6 in their last 10 and now 6.5 games behind the Jays in the American League East. The Rockies have the ninth smallest payroll in MLB but the Yankees have the second highest at US$298 million, with approximately $40 million of that going to superstar Aaron Judge. The Pinstripes also feature slugger Giancarlo Stanton ($32 million), Cody Bellinger ($27.5 million) and Paul Goldschmidt ($12.5 million). Those four players themselves earn $112 million. The Rockies' payroll is $122 million all in. Article content Needless to say, the Yankees have been the talk of the town in the Big Apple and not in a good way.
Calgary Herald
2 days ago
- Calgary Herald
Tom Mayenknecht: Tennis finds new star in Canadian Victoria Mboko; NFL also has big week
Bulls of the week Article content It was a bullish week for both the National Football League and ESPN, with the NFL gaining a 10 per cent stake in the American cable giant and the Disney-owned sports network taking on the rights to and operations of NFL Network and Red Zone TV. It's a game-changing deal for the way leagues and their media rights holders relate to one another, on and off the field, so to speak. Watch for it to lead to many similar arrangements involving other leagues and their rights holders. It will only further elevate the upside and preferred position held by official rights holders, not only in the NFL but across all major men's and women's professional sports leagues operating in North America. Yet it will also lead to ongoing scrutiny and second-guessing of league decisions given the coziness and high stakes of the ownership relationship. Article content Article content Article content The Toronto Blue Jays had an all-time franchise-high of 45 runs scored over a three-game series as they swept the hapless Colorado Rockies in lopsided fashion this week (15-1, 10-4 and 20-1). They also became the first Major League Baseball franchise since 1900 to amass 63 hits in a three-game series, with 13 home runs, 13 doubles, one triple and 36 singles. The Jays go into the weekend with a 68-48 record, 20 games above .500 and four games ahead of the Boston Red Sox in the American League East. The Rockies series was a lot of fun for the Jays and their fans, but make no mistake, their opposition will be a lot tougher against the 66-49 Los Angeles Dodgers, 66-48 Chicago Cubs and 60-56 Texas Rangers over the next week. Article content Article content Yet the biggest winner this week in the business of sport was Canadian 18-year-old Victoria Mboko of Burlington, Ont. She became the third Canadian woman to win the National Bank Open presented by Rogers (Canadian Open), following in the footsteps of 2019 champion Bianca Andreescu. Mboko's ascent to tennis champion and Canadian sports hero is both improbable and remarkable, as was her final match win over four-time Grand Slam women's singles champion Naomi Osaka (2-6, 6-4, 6-1). Wins over four Grand Slam major champions will take her from a world ranking of 85th to begin the tournament to within the top-25 on the WTA Tour. This from a player who began the year outside of the top-300 in the world. Article content Article content To put the sport business side of the Mboko story into proper context, consider this: She earned $752,275 for the win. That single tournament score is more than her year-to-date career earnings of $458,001. She's now 53-9 in 2025, coming off only her seventh time playing in a WTA Tour main draw. Article content Perhaps most unfathomable about the come-from-behind win over Osaka is that Mboko was playing with a wrist injury suffered the night before in her semifinal win over former Wimbledon champion Elena Rybakina. Article content Article content The flip side of the big three-game sweep at Coors Field in mile high Denver is how pathetic the Rockies are. It's an embarrassment to baseball that a team can be 30-84, winning barely once every four games; 35.5 games behind in the National League West. Article content Yet arguably the biggest bears of the week are the New York Yankees, 4-6 in their last 10 and now 6.5 games behind the Jays in the American League East. The Rockies have the ninth smallest payroll in MLB but the Yankees have the second highest at US$298 million, with approximately $40 million of that going to superstar Aaron Judge. The Pinstripes also feature slugger Giancarlo Stanton ($32 million), Cody Bellinger ($27.5 million) and Paul Goldschmidt ($12.5 million). Those four players themselves earn $112 million. The Rockies' payroll is $122 million all in. Article content Needless to say, the Yankees have been the talk of the town in the Big Apple and not in a good way.
Cision Canada
3 days ago
- Cision Canada
Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE) Français
ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and underscores the company's commitment to delivering innovative medicines to the HAE community OTTAWA, Canada, Aug. 8, 2025 /CNW/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that Health Canada has granted a marketing authorization for ANDEMBRY ® (garadacimab) for routine prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ANDEMBRY is a monoclonal antibody designed to target activated FXII (FXIIa), a plasma protein at the top of the HAE cascade that plays a key role in attacks of swelling in people with HAE. ANDEMBRY reinforces CSL's decades-long commitment to advancing innovation for the HAE community and is authorized with a prefilled pen for subcutaneous self-injection. "As the first monoclonal antibody discovered and developed entirely by CSL, ANDEMBRY is a reflection of our commitment to delivering innovative treatment options for the patients who need them most," said Bill Mezzanotte, MD, Executive Vice President, Head of R&D, CSL. "This approval marks a major step forward in HAE care, building on our more than 40-year legacy in HAE research and treatment optimization to offer people living with this life-threatening condition long-term control over their disease along with a convenient administration method." HAE is a rare, chronic, and potentially life-threatening genetic disorder characterized by recurrent and unpredictable attacks of angioedema. Attacks of HAE are often painful and can affect multiple sites of the body, including the abdomen, larynx, face, and extremities. ANDEMBRY inhibits the top of the HAE cascade while other HAE therapies target downstream mediators. "Health Canada's authorization of ANDEMBRY represents a significant advancement in the treatment of HAE," said Dr. Stephen Betschel, Chair of the Canadian Hereditary Angioedema Network. "This new therapy, which targets factor XIIa, offers a promising approach to preventing HAE attacks. By addressing the underlying mechanisms of HAE, ANDEMBRY provides an important option for patients to reduce the frequency of their attacks of angioedema. Having a new treatment option will further enhance our ability to help our patients manage their HAE effectively." The Health Canada authorization is based on data from the pivotal placebo-controlled Phase 3 VANGUARD trial evaluating the efficacy and safety of ANDEMBRY. The pivotal study (The Lancet, April 2023) demonstrated that treatment with ANDEMBRY: Reduced HAE attacks by a median of more than 99 percent and a reduced least squares mean of 89.2 percent, compared to placebo. Led to 62 percent of ANDEMBRY-treated patients remaining attack-free throughout the treatment period. The most common adverse reactions in the pivotal trial were injection site erythema, injection site bruising, injection site pruritus, injection site urticaria, headache, and abdominal pain. A published interim analysis (Allergy, Oct 2024) of the ongoing open-label extension study (median ANDEMBRY exposure of 13.8 months) showed that ANDEMBRY has a favorable long-term safety profile and provides sustained reductions in HAE attacks. "We are pleased to see Health Canada's authorization of ANDEMBRY for HAE and look forward to its availability in Canada," said Michelle Cooper, President, HAE Canada. "As the first treatment to target the top of the HAE cascade, this therapy represents a significant advancement in preventing HAE attacks. We believe it will provide meaningful benefits to the HAE community in Canada." This regulatory approval for ANDEMBRY is another crucial step in building toward the global availability of ANDEMBRY, which was recently approved in Australia, the United Kingdom (UK), the European Union (EU), Japan, Switzerland, and the United States (US). About HAE HAE is a rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE is caused by deficient or dysfunctional C1-INH, a protein in the blood that helps to control inflammation. Inadequate amounts of properly functioning C1-INH can lead to the accumulation of fluid in body tissues, causing considerable swelling referred to as angioedema. HAE attacks can affect many parts of the body, including the face, abdomen, larynx, and extremities. Patients who have abdominal attacks of HAE can experience extreme pain, diarrhea, nausea, and vomiting caused by swelling of the intestinal wall. HAE attacks that involve the face or throat can result in airway closure, asphyxiation and, if left untreated, death. About ANDEMBRY ANDEMBRY is a novel monoclonal antibody inhibiting factor XIIa (anti-FXIIa mAb) that has completed the Phase 3 pivotal study as a once-monthly subcutaneous prophylactic treatment for attacks related to HAE, a form of bradykinin-mediated angioedema. ANDEMBRY is CSL's first homegrown recombinant monoclonal antibody to gain Health Canada approval. It was discovered and optimized by scientists at CSL's Bio21-based research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. ANDEMBRY uniquely inhibits the plasma protein, FXIIa. FXII is the first protein activated in the HAE pathway, initiating the cascade of events leading to an HAE attack. By targeting activated FXII (FXIIa), ANDEMBRY inhibits this cascade at the top as compared to other HAE therapies that target downstream mediators. About t he VANGUARD Trial The multicenter, randomized, double-blind, parallel-group VANGUARD trial evaluated the efficacy and safety of ANDEMBRY, a first-in-class monoclonal antibody, as a prophylactic treatment for patients with hereditary angioedema. Patients aged 12 years and older with HAE type I or II underwent screening and a run-in study period to verify a baseline attack rate. Patients were randomized 3:2 to receive a loading dose of 400 mg followed by 200 mg of ANDEMBRY monthly (n=39) or volume matched placebo monthly (n=25) subcutaneously. After the six-month treatment period, patients were given the opportunity to continue into the open-label extension study, which is currently ongoing. The ongoing open-label extension of the Phase 3 VANGUARD study is evaluating the long-term safety and efficacy of ANDEMBRY (200 mg monthly) for the prophylactic treatment of hereditary angioedema attacks. Important Information for Canada For more information and a complete risk/benefit profile, please refer to the Product Monograph available here. About CSL CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat Hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL, visit Media Contact Valerie Bomberger, CSL Office: +1 610-291-5388 Mobile: +1 267-280-3829 Email: [email protected] Etanjalie Ayala CSL Behring Mobile: +1 610 297 1069 Email: [email protected] Greg Healy CSL Mobile: +1 610-906-4564 Email: [email protected] In Australia: Kim O'Donohue CSL Mobile: +61 449 884 603 Email: [email protected] Brett Foley CSL Mobile: +61 461 464 708 Email: [email protected] Investors Contact Chris Cooper CSL Email: [email protected] +61 455 022 740 SOURCE CSL
